This content is from: Premium

ValueAct’s Valeant Problem

Jeffrey Ubben’s activist firm built its fortunes in part based on its early success with now-struggling Valeant Pharmaceuticals International. With Valeant battling a 90 percent drop in its share price, can ValueAct outrun collateral damage to its reputation?

       Photo credit: BloombergBy Michelle Celarier ValueAct Capital Management’s Jeffrey Ubben has carefully cultivated a reputation as a good-guy activist who works with management to get results — a reputation that was built in part on his tremendous success with Canadian drugmaker Valeant Pharmaceuticals International. Valeant soared for years, helping fuel such

To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.

Related Content